What NEA Management Company, LLC reported holding on Form 13F for the quarter ended Sep 30, 2026.
CIK 1512848 · Filed Nov 16, 2026
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
| 7.4M |
| ±0% |
| $192.2M |
| 14.1% |
TRVITrevi Therapeutics, Inc. | 13.2M | ±0% | $189.3M | 13.9% |
CELCCelcuity Inc. | 1.7M | ±0% | $136M | 10% |
SVRASavara Inc | 24.5M | ±0% | $126.3M | 9.3% |
ZBIOZenas BioPharma, Inc. | 4M | ±0% | $108.5M | 8% |
GLUEMonte Rosa Therapeutics, Inc. | 6.7M | −13.0% | $79.8M | 5.9% |
AUPHAurinia Pharmaceuticals Inc. | 4M | ±0% | $64.3M | 4.7% |
COURCoursera, Inc. | 12.9M | ±0% | $63.8M | 4.7% |
CRSPCRISPR Therapeutics AG | 1.1M | ±0% | $58.6M | 4.3% |
ORICOric Pharmaceuticals, Inc. | 4.1M | ±0% | $55.5M | 4.1% |
PHATPhathom Pharmaceuticals, Inc. | 2M | ±0% | $14.3M | 1% |
KRROKorro Bio, Inc. | 1.3M | ±0% | $12.9M | 0.9% |
X4 Pharmaceuticals, Inc.COM | 3.2M | ±0% | $9.4M | 0.7% |
NKTXNkarta, Inc. | 3.6M | ±0% | $9.4M | 0.7% |
CSBRChampions Oncology, Inc. | 1.7M | ±0% | $8.6M | 0.6% |
BDTXBlack Diamond Therapeutics, Inc. | 4.4M | ±0% | $8.4M | 0.6% |
IVAInventiva S.A. | 1.5M | ±0% | $5.4M | 0.4% |
CVRXCVRx, Inc. | 2M | ±0% | $3.4M | 0.3% |
MRKRMarker Therapeutics, Inc. | 1.6M | ±0% | $1.7M | 0.1% |
LONALeonaBio, Inc. | 464.4K | ±0% | $1.7M | 0.1% |
OKUROnKure Therapeutics, Inc. | 478.5K | ±0% | $1.3M | 0.1% |
SNTISenti Biosciences Holdings, Inc. | 3.8M | ±0% | $1.2M | 0.1% |
IMAImageneBio, Inc. | 50K | ±0% | $229K | 0.1% |
GOSSGossamer Bio, Inc. | 12.5K | −98.8% | $148.1K | 0.1% |